Market Analysis Open Access

market Analysis

Abstract

 Market  Analysis:                        The global market for drug delivery systems was valued at nearly $176.7 billion in 2012 and is expected to reach nearly $182 billion in 2013. BCC Research projects the market to grow to nearly $212.8 billion by 2019, and register a 5-year compound annual growth rate of 3.2% from 2013 to 2019.  The global pharmaceutical drug delivery market is split up into four major regions, namely, Europe, Asia Pacific, North America, and the remaining of the World. This technical market research report encompasses drug delivery systems in pharmaceutical and biotechnology markets. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, and others.US demand for drug delivery products will inflate 7.4 percent annually to $134 billion in 2015. The finest growth opportunities will appear in dosage formulations that proceed the nature of therapy for autoimmune conditions, neurological disorders, heart disease, cancer, and other debilitating health problems. Insistence for oral drug delivery products will rise up to 4.3 percent annually to over $52 billion in 2015. Controlled-release formulations will direct the big share of sales, but will lose some growth due to patent cessation on various big-selling sustained-release therapies. Nanoparticulate medicines will note some of the quick growth among oral drug delivery products based on current products and the high value-added nature of indications served. This study analyzes the $93.8 billion US drug delivery system industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by excipient (e.g., polymers, cellulose, minerals), product type (e.g., oral, parenteral, inhalation, implantable, transdermal) and application (e.g., central nervous system, respiratory, hormones, gastrointestinal). The drug delivery market is forecast to reach USD 1,694.7 billion by 2023 from USD 1,244.4 billion in 2018, at a CAGR of 6.4% during the projected period. Growth in this market is mainly directed by the increase frequency of chronic diseases, growth in technological advancements and biologics market, and new product launches. On the other hand, the danger of needle stick injuries and the rising pricing pressure are anticipated to ultimatum market growth in the coming years. Drug delivery system is a process of administering a pharmaceutical compound in humans or animals to achieve a therapeutic effect. The new and emerging drug delivery systems are much advanced over traditional systems in terms of their site specificity, accuracy, efficacy, decreased dosing frequency, mechanism of action and reductions in toxic metabolites. These advantages of advanced drug delivery systems are driving significant growth in the global drug delivery markets. The market will rise  at a good pace in the coming few years because of thorough discovery and development of new drug delivery systems in research-based pharmaceutical companies, which is again a cause  for planned association and successful  partnerships between pharmaceutical companies. The global market for advanced drug delivery systems is segmented of basis of 1) Type (Oral drug delivery system, Injection-based drug delivery system, Inhalation/Pulmonary drug delivery system, Transdermal drug delivery system, Transmucosal drug delivery system and Carrier based drug delivery system), 2) Application (Cardiovascular diseases, Oncology, Urology, Diabetes, CNS, Ophthalmology, Inflammatory diseases, Infections and Others), 3) Technology (Prodrug, Implants and Intrauterine devices (IUDs), Targeted drug delivery, Polymeric drug delivery) and 4) Geographic Regions. In the last decade, the demand for drug delivery systems has shot up rapidly and the increasing demand is due to the increasing number of patients and diagnoses recorded for Cancer and Diabetes. The biggest contributor to this system is the advanced technology that has not only contributed in terms of minimizing efforts, reducing errors, but also growth in efficiency and innovation. Pharmaceutical corporations have widely prescribed medicines as there has been so much of improvement due to accommodation of technology and also to recover and maintain steady economics for the large spending in R&D, with whose help there came so many innovations and improved medicines. In addition, patients’ wellness has progresses substantially with ever improving mechanization and possibilities of massive breakthroughs in this field have propelled the drug delivery industry to a new height, and also in having an astounding growth in drug delivery systems for hormones and cardiology agents. The global market for advanced drug delivery system is expected to amount for the value of $196.4 billion by 2014 at 7.2% CAGR. The global drug delivery market is projected to rise with a CAGR of 11.26% over the forecast years of 2018-2026. Factors such as the more frequency of chronic diseases around the globe, technological improveents and rising demand for effective drug delivery mechanisms are driving growth in the drug delivery market. The global drug delivery systems market was valued approximately US$ 510.0 Bn in 2016 and is anticipated to expand at a CAGR of over 6.9% from 2017 to 2025 to reach approximately US$ 900 Bn by 2025. The North America NDDS market is expected to witness a CAGR of 8.7% during the forecast period, 2018-2023. Important companies manage in the global drug delivery systems market and profiled in the report include AstraZeneca plc., Novartis AG , Bayer AG, Amgen Inc.,  , Johnson and Johnson Services, Pfizer, Inc.,  Inc., Baxter International, Inc., Dickinson & Company Boston Scientific Corporation, and Becton, Drug delivery mention to technologies, formulations, approaches, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its required therapeutic effect.The market is currently estimated to be worth USD 18.5 billion for the year 2018 and is expected to reach USD 51.7 billion by the end of 2025. The CAGR during this period of the forecast is 22.78%. Currently, North America dominates the global market owing to the fact that there is greater awareness and increase per capita income. The USA is the biggest market in the world, followed by Canada. This escalation is developing the need to analyze, review and forecast the growth of the drug delivery devices market. Owing to the rapid evolution of the market in the use of injectable drug delivery technology, medical device companies that are able to launch new innovative equipment will be rewarded with huge benefits.  

 Jennifer Edward

To read the full article Download Full Article